THERAVET SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.371 EUR | -2.37% |
|
-18.46% | -74.41% |
| May. 21 | TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study | CI |
| May. 07 | FOMO is Back |  |
Business Summary
At the end of 2023, the company had a portfolio of 2 products in the clinical development phase: Visco-Vet for the treatment of limping associated with osteoarthritis in dogs and Biocera-Vet for osseointegration and bone remodeling.
Number of employees: 6
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Osteoarticular Treatment
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +25.31% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Europe
72.9
%
| - | - | 0 | 72.9 % | - |
North America
25.2
%
| - | - | 0 | 25.2 % | - |
Asia
1.9
%
| - | - | 0 | 1.9 % | - |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-11-20 | |
Rodolphe Lebrun
DFI | Director of Finance/CFO | - | 23-10-23 |
Celine Molle
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sabrina Ena
COO | Chief Operating Officer | - | 14-06-30 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-11-20 | |
Simon Wheeler
CHM | Chairman | - | 21-12-19 |
Nesya Goris
BRD | Director/Board Member | - | 21-12-19 |
Company contact information
Sector
Sales per region
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -74.41% | 1.3M | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- ALVET Stock
- Company TheraVet SA
